Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Lorenzo Bertani"'
Autor:
Jessica Cusato, Davide Giuseppe Ribaldone, Michela Helga Falzone, Alessandra Manca, Miriam Antonucci, Alice Palermiti, Giorgio Maria Saracco, Linda Ceccarelli, Francesco Costa, Andrea Bottari, Ginevra Fornaroli, Gian Paolo Caviglia, Antonio D’Avolio, Lorenzo Bertani
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 824 (2024)
Over the years, vedolizumab (VDZ) has emerged as a more effective target therapy for inflammatory bowel disease. The aim of this work was to analyze a cohort of inflammatory bowel disease patients, evaluating the association between VDZ serum concent
Externí odkaz:
https://doaj.org/article/614fe017fa1c4fbdb0ac307ceb543044
Autor:
Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induce
Externí odkaz:
https://doaj.org/article/e1df2d0bb34a4efe88e26cf19e6d58b1
Autor:
Brigida Barberio, Linda Cingolani, Cristina Canova, Giulia Barbieri, Renato Sablich, Maria Teresa Urbano, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Antonio Ferronato, Andrea Buda, Piera Melatti, Davide Massimi, Edoardo Vincenzo Savarino, Fabiana Zingone
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lack
Externí odkaz:
https://doaj.org/article/894dccb3e3904386a4d6bb5291f7f2fc
Autor:
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical
Externí odkaz:
https://doaj.org/article/2597c903fe2c465ea68be45f74e33152
Autor:
Riccardo Capecchi, Paola Migliorini, Federico Zanzi, Simona Maltinti, Ilaria Puxeddu, Nicola de Bortoli, Massimo Bellini, Francesco Costa, Santino Marchi, Lorenzo Bertani
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Ulcerative colitis (UC) is a chronic relapsing disease, which needs a continue monitoring, especially during biological therapies. An increasing number of patients is treated with anti-Tumor Necrosis factor (TNF) drugs, and current resear
Externí odkaz:
https://doaj.org/article/75ca6bfff6614c2d995803f3c06b4dfc
Autor:
Sonia Facchin, Andrea Buda, Romilda Cardin, Nada Agbariah, Fabiana Zingone, Manuela De Bona, Debora Zaetta, Lorenzo Bertani, Matteo Ghisa, Brigida Barberio, Edoardo Vincenzo Savarino
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are un
Externí odkaz:
https://doaj.org/article/92aff6dc847040a9a81ffbf858202bfc
Autor:
Pierfrancesco Visaggi, Edoardo Savarino, Giusi Sciume, Teresa Di Chio, Francesco Bronzini, Salvatore Tolone, Marzio Frazzoni, Camilla Pugno, Matteo Ghisa, Lorenzo Bertani, Massimo Bellini, Vincenzo Savarino, Diego Peroni, Santino Marchi, Nicola de Bortoli
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
In the absence of secondary causes, eosinophilic esophagitis (EoE) is a chronic, local, progressive, T-helper type 2 immune-mediated disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. In the last 20
Externí odkaz:
https://doaj.org/article/206de50fdf8d40e888711af23e72255b
Autor:
Luca Antonioli, Matteo Fornai, Carolina Pellegrini, Lorenzo Bertani, Zoltan H. Nemeth, Corrado Blandizzi
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/98c61db4b79a44f4a915df14770b1723
Autor:
Jessica Cusato, Lorenzo Bertani, Miriam Antonucci, Cristina Tomasello, Gian Paolo Caviglia, Simone Dibitetto, Alessandro Massano, Michela Mangia, Jacopo Mula, Linda Ceccarelli, Francesco Costa, Federico Zanzi, Marco Astegiano, Davide Giuseppe Ribaldone, Antonio D’Avolio
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1230 (2021)
Adalimumab (ADA) is a human anti-tumor necrosis factor (TNF-α) monoclonal antibody used in inflammatory bowel diseases, such as Crohn’s disease (CD). Vitamin-D (VD) is important for biological functions, such as the modulation of expression of gen
Externí odkaz:
https://doaj.org/article/d9f54714b946469ba8a348addaa37103
Autor:
Luca Antonioli, Carolina Pellegrini, Matteo Fornai, Laura Benvenuti, Vanessa D’Antongiovanni, Rocchina Colucci, Lorenzo Bertani, Clelia Di Salvo, Giorgia Semeghini, Concettina La Motta, Laura Giusti, Lorenzo Zallocco, Maurizio Ronci, Luca Quattrini, Francesco Angelucci, Vito Coviello, Won-Keun Oh, Quy Thi Kim Ha, Zoltan H. Németh, Gyorgy Haskó, Corrado Blandizzi
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 12, p 6325 (2021)
Acadesine (ACA), a pharmacological activator of AMP-activated protein kinase (AMPK), showed a promising beneficial effect in a mouse model of colitis, indicating this drug as an alternative tool to manage IBDs. However, ACA displays some pharmacodyna
Externí odkaz:
https://doaj.org/article/4c336995eae3454b93eedb2acc5c7adc